These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 15030117

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L.
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI, RUSSLAN Study Investigators.
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [Abstract] [Full Text] [Related]

  • 12. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L, Põder P.
    Ann Med; 2007 Sep; 39(1):2-17. PubMed ID: 17364447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Levosimendan: from basic science to clinical practice.
    Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A.
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
    Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
    Lancet; 2002 Jul 20; 360(9328):196-202. PubMed ID: 12133653
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan 20; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 17. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, Zhi YH.
    J Zhejiang Univ Sci B; 2013 May 20; 14(5):400-15. PubMed ID: 23645177
    [Abstract] [Full Text] [Related]

  • 18. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L.
    Curr Cardiol Rep; 2000 May 20; 2(3):233-43. PubMed ID: 10980898
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series.
    Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J.
    Hellenic J Cardiol; 2007 May 20; 48(2):80-8. PubMed ID: 17489345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.